The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early prediction of prognosis in advanced solid tumor patients using tumor growth rates with g score in early phase clinical trials.
 
Kana Kurokawa
No Relationships to Disclose
 
Takahiro Kogawa
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo
Speakers' Bureau - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sakyo; Eisai; Gilead Sciences; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Lilly (Inst)
 
Ippei Miyamoto
No Relationships to Disclose
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Eriko Miyawaki
No Relationships to Disclose
 
Haruka Ozaki
No Relationships to Disclose
 
Yohei Arihara
No Relationships to Disclose
 
Akihiro Ohmoto
No Relationships to Disclose
 
Shota Fukuoka
No Relationships to Disclose
 
Yukinori Ozaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Lilly; Pfizer
 
Makiko Ono
Speakers' Bureau - Chugai Pharma; Lilly Japan
Research Funding - Astellas Pharma (Inst); Eisai (Inst); Pfizer
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Mayu Yunokawa
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Eisai; MSD; Sanofi; Takeda
 
Shunji Takahashi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Novartis
Research Funding - Lilly Japan (Inst)
 
Takehito Shukuya
Honoraria - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nippon kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Takeda (Inst)
 
Kazuhisa Takahashi
Honoraria - AstraZeneca; AstraZeneca; BioMerieux Japan Ltd.; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Insmed GK.; Janssen; Kyorin; Kyorin; MSD K.K; MSD K.K; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sawai Pharmaceutical Co; Shionogi; Shionogi; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical
Research Funding - Chugai Pharma; Chugai Pharma; MSD K. K.; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin; Loxo/Lilly (Inst); Merck KGaA; MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst)